Publications by authors named "Sven Mensing"

Claim this Profile
P
Predictive AI in Clinical Pharmacology: A Call to Action to Develop Robust Benchmarking Practices.
Ana Victoria Ponce-Bobadilla, Dominic Bräm, Ali Farnoud, Holger Fröhlich, Alexander Janssen, Sven Mensing

CPT Pharmacometrics Syst Pharmacol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Semi-mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine.
Neha Thakre, Corinna Maier, Jiuhong Zha, Benjamin Engelhardt, Johannes E Wolff, Sven Mensing

CPT Pharmacometrics Syst Pharmacol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Practical guide to SHAP analysis: Explaining supervised machine learning model predictions in drug development.
Ana Victoria Ponce-Bobadilla, Vanessa Schmitt, Corinna S Maier, Sven Mensing, Sven Stodtmann

Clin Transl Sci· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetic and Exposure-Response Modeling to Inform Risankizumab Dose Selection in Patients With Ulcerative Colitis.
Neha Thakre, Aline Goebel, Insa Winzenborg, Ahmed A Suleiman, Ronilda D'Cunha, Sven Mensing

Clin Pharmacol Ther· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrating machine learning with pharmacokinetic models: Benefits of scientific machine learning in adding neural networks components to existing PK models.
Diego Valderrama, Ana Victoria Ponce-Bobadilla, Sven Mensing, Holger Fröhlich, Sven Stodtmann

CPT Pharmacometrics Syst Pharmacol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship Between Venetoclax Exposure and Undetectable Minimal Residual Disease Rates in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of Six Clinical Studies.
Sathej Gopalakrishnan, Rajeev Menon, Ahmed A Suleiman, Arnon P Kater, Stephan Stilgenbauer, Sven Mensing

Hemasphere· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Opportunities and Challenges of Disease Progression Modeling in Drug Development - An IQ Perspective.
Kosalaram Goteti, Nathan Hanan, Mindy Magee, Jessica Wojciechowski, Sven Mensing

Clin Pharmacol Ther· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pooled Population Pharmacokinetic Analyses of Venetoclax in Patients Across Indications and Healthy Subjects from Phase 1, 2, and 3 Clinical Trials.
Jingqi Q X Gong, Ahmed A Suleiman, Rajeev Menon, Rong Deng, Sven Mensing

J Clin Pharmacol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the Impact of Immunogenicity and Improving Prediction of Trough Concentrations: Population Pharmacokinetic Modeling of Adalimumab in Patients with Crohn's Disease and Ulcerative Colitis.
Ana Victoria Ponce-Bobadilla, Sven Stodtmann, Mong-Jen Chen, Insa Winzenborg, Sven Mensing

Clin Pharmacokinet· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-Response Model With Time-Varying Predictors to Estimate the Effects of Veliparib in Combination With Carboplatin/Paclitaxel and as Monotherapy: Veliparib Phase 3 Study in BRCA-Mutated Advanced Breast Cancer (BROCADE3) Trial.
Sven Stodtmann, Doerthe Eckert, Rujuta Joshi, Silpa Nuthalapati, Christine K Ratajczak, Sven Mensing

J Clin Pharmacol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioavailability Evaluation of Venetoclax Lower-Strength Tablets and Oral Powder Formulations to Establish Interchangeability with the 100 mg Tablet.
Mohamed Badawi, Xin Chen, Patrick Marroum, Ahmed A Suleiman, Sven Mensing

Clin Drug Investig· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-naïve acute myeloid leukemia who are ineligible for intensive chemotherapy.
Deanna Brackman, Doerthe Eckert, Rajeev Menon, Ahmed Hamed Salem, Jalaja Potluri, Sven Mensing

Hematol Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Population Pharmacokinetic Meta-Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients.
Sven Stodtmann, Silpa Nuthalapati, Doerthe Eckert, Sreeneeranj Kasichayanula, Rujuta Joshi, Sven Mensing

J Clin Pharmacol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated Mechanistic Model of Minimal Residual Disease Kinetics With Venetoclax Therapy in Chronic Lymphocytic Leukemia.
Sathej Gopalakrishnan, William Wierda, Brenda Chyla, Rajeev Menon, Dale Miles, Sven Mensing

Clin Pharmacol Ther· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181).
John Powderly, Alexander Spira, Shunsuke Kondo, Toshihiko Doi, Jason J Luke, Sven Mensing

Clin Transl Sci· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetics of Glecaprevir/Pibrentasvir in HCV-infected Japanese Subjects in Phase 3 CERTAIN-1 and CERTAIN-2 Trials.
Ahmed Abbas Suleiman, Chih-Wei Lin, Wei Liu, Doerthe Eckert, Sven Mensing

J Clin Pharmacol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Model-Informed Dosing of Venetoclax in Healthy Subjects: An Exposure-Response Analysis.
Nimita Dave, Sathej Gopalakrishnan, Sven Mensing, Ahmed Hamed Salem

Clin Transl Sci· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-response analysis to inform the optimal dose of veliparib in combination with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer patients.
Silpa Nuthalapati, Sven Stodtmann, Stacie Peacock Shepherd, Christine K Ratajczak, Sven Mensing

Cancer Chemother Pharmacol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
Suresh Agarwal, Sathej Gopalakrishnan, Sven Mensing, Jalaja Potluri, John Hayslip

Hematol Oncol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Integrated Population Pharmacokinetic Model Versus Individual Models of Depatuxizumab Mafodotin, an Anti-EGFR Antibody Drug Conjugate, in Patients With Solid Tumors Likely to Overexpress EGFR.
Rajendar K Mittapalli, Sven Stodtmann, Anna Friedel, Rajeev M Menon, Earle Bain, Sven Mensing

J Clin Pharmacol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Hepatitis C Virus-Infected Cirrhotic and Non-cirrhotic Patients: Analyses Across Nine Phase III Studies.
Sathej Gopalakrishnan, Sven Mensing, Rajeev M Menon, Jiuhong Zha

Clin Pharmacokinet· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma.
Apurvasena Parikh, Sathej Gopalakrishnan, Kevin J Freise, Maria E Verdugo, Rajeev M Menon, Sven Mensing

Leuk Lymphoma· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of Exposure-Response Analyses to Establish the Pharmacodynamic Similarity of a Once-Daily Regimen to an Approved Twice-Daily Dosing Regimen for the Treatment of HCV Infection.
Akshanth R Polepally, Haoyu Wang, Patrick J Marroum, Mukul Minocha, Balakrishna Hosmane, Sven Mensing

AAPS J· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.
Kevin J Freise, Aksana K Jones, Doerthe Eckert, Sven Mensing, Shekman L Wong

Clin Pharmacokinet· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials.
Sven Mensing, Doerthe Eckert, Shringi Sharma, Akshanth R Polepally, Amit Khatri

Br J Clin Pharmacol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis